Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136058
Status:
COMPLETED
Last Update Posted:
2011-12-16
First Post:
2005-08-25
Brief Title:
Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
Sponsor:
University of Alberta
Organization:
University of Alberta
Study Overview
Official Title:
Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to determine if an intervention with a fracture manager to arrange bone densitometry after a hip fracture is more effective in diagnosing and treating osteoporosis when compared to usual care Usual care consists of no intervention to arrange bone mineral density BMD testing or therapy other than what normally occurs in the community The investigators postulate that a fracture manager will be more effective in getting BMD done and in starting appropriate therapy
Detailed Description:
All hip fracture patients in the Edmonton area will be screened for eligibility mini-mental status 20 not on active osteoporosis pharmacologic therapy All patients will have informed consent obtained Patients will be randomized to 2 groups
Group 1 Active intervention The fracture manager will arrange for bone densitometry DEXA to be done 3-6 months after the fracture If the patient meets standard criteria for osteoporosis therapy with a bisphosphonate alendronate or risedronate will be instituted by the study physicians
Group 2 Usual care Patients will receive basic information about calcium and vitamin D and osteoporosis and told to follow up with their family doctor At 6 months patients will be contacted to determine if they have had a BMD done or started on active drug osteoporosis therapy If not the fracture manager will arrange the BMD and if appropriate therapy will be started by the study physicians
All patients will be followed for 1 year The primary endpoints are the number of patients who get a BMD and the number who are started on active osteoporosis therapy
Group 1 Active intervention The fracture manager will arrange for bone densitometry DEXA to be done 3-6 months after the fracture If the patient meets standard criteria for osteoporosis therapy with a bisphosphonate alendronate or risedronate will be instituted by the study physicians
Group 2 Usual care Patients will receive basic information about calcium and vitamin D and osteoporosis and told to follow up with their family doctor At 6 months patients will be contacted to determine if they have had a BMD done or started on active drug osteoporosis therapy If not the fracture manager will arrange the BMD and if appropriate therapy will be started by the study physicians
All patients will be followed for 1 year The primary endpoints are the number of patients who get a BMD and the number who are started on active osteoporosis therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AHFMR 200100791-2 | None | None | None |